公告显示，截至公告披露日，楼国梁合计持有公司股份712.02万股，占公司总股本股的3.0882%。 北京商报讯（记者 丁宁）2月12日晚间，昊海生科（688366）发布公告称，公司股东楼国梁因自身资金 需要，计划自公告披露之日起3个交易日后3个月内，通过集中竞价和大宗交易方式合计减持不超过100 万股的公司股份，占公司总股本的比例不超过0.4337%。 ...

证券代码：688366 证券简称：昊海生科 公告编号：2026-001 上海昊海生物科技股份有限公司 减持计划的主要内容：楼国梁先生因自身资金需要，计划自本公告披露 之日起 3 个交易日后 3 个月内，通过集中竞价和大宗交易方式合计减持不超过 1,000,000 股的公司股份，占公司总股本 230,561,595 股的比例不超过 0.4337%， 其中，通过集中竞价方式减持不超过 1,000,000 股，通过大宗交易方式减持不超 过 1,000,000 股。减持价格将根据二级市场价格确定。 楼国梁先生于 2021 年 7 月 7 日起不再为公司 5%以上的股东，本次减持 股份计划系基于楼国梁先生于公司在上海证券交易所科创板上市时的公开承诺 所作出。 | 股东名称 | 楼国梁 | | | | --- | --- | --- | --- | | | 控股股东、实控人及一致行动人 | □是 | √否 | | 股东身份 | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | 一、减持主体的基本情况 1 | | 其他：5%以下股东 | | --- | --- | | ...

（记者 王晓波） 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 每经AI快讯，昊海生科2月12日晚间发布公告称，截至本公告披露日，楼国梁先生合计持有上海昊海生 物科技股份有限公司股份约712万股，占公司总股本约2.31亿股的3.0882%。相关股份来源于公司首次公 开发行前以及上市后公司实施资本公积金转增股本取得的股份，其中，首次公开发行前股份已于2020年 10月30日解除限售并上市流通，资本公积金转增股本取得的股份于2024年6月20日上市流通。 楼国梁先生因自身资金需要，计划自本公告披露之日起3个交易日后3个月内，通过集中竞价和大宗交易 方式合计减持不超过100万股的公司股份，占公司总股本约2.31亿股的比例不超过0.4337%，其中，通过 集中竞价方式减持不超过100万股，通过大宗交易方式减持不超过100万股。减持价格将根据二级市场价 格确定。 ...

Core Viewpoint - The company focuses on rapidly developing treatment areas such as medical aesthetics, wound care, ophthalmology, orthopedics, and surgery, accelerating the transformation of innovative results [2] Group 1: Product Development - The company has received approvals for high-end hyaluronic acid products "Haimi" and "Haimi Moon White," as well as various mid-range and high-end artificial lenses and high-permeability corneal shaping lenses [2] - The company is expanding its product line in medical aesthetics and ophthalmology, with several key R&D projects underway, including painless cross-linked hyaluronic acid, medical cross-linked chitosan gel, enhanced water-light injection agents, and linear precision cross-linked water-light injection agents [2] Group 2: R&D Focus - Ongoing R&D projects include hydrophilic continuous vision artificial lenses, hydrophobic mold-injected extended depth of focus artificial lenses, intraocular filling biological gels, aqueous permeable PRL, high-permeability scleral lenses, and new high-permeability (DK180) corneal shaping lenses [2]

Core Viewpoint - Haohai Biological Technology has successfully expanded its product lines in the medical aesthetics and ophthalmology sectors, enhancing its global market presence and growth potential [2]. Group 1: Medical Aesthetics - Haohai's subsidiary Bioxis has successfully launched its Cytosial hyaluronic acid product in Europe, South America, and the Middle East, achieving sales in these regions [2]. Group 2: Ophthalmology - The company's core platform Contamac supplies approximately 17 million optical raw materials annually to contact lens and artificial lens manufacturers in over 70 countries worldwide [2]. - The establishment of these platforms is expected to continuously empower the global layout of the company's product lines, opening up broader development opportunities [2].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,740 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,74 ...

Core Viewpoint - Haohai Biological Technology Co., Ltd. is experiencing a decline in revenue and net profit, with significant changes in shareholder structure and financing activities [2][3]. Group 1: Financial Performance - For the period from January to September 2025, Haohai Biological reported operating revenue of 1.899 billion yuan, a year-on-year decrease of 8.47% [2]. - The net profit attributable to shareholders for the same period was 305 million yuan, reflecting a year-on-year decline of 10.63% [2]. Group 2: Shareholder and Financing Activities - As of February 2, 2025, the number of shareholders increased to 8,388, representing a 7.44% rise compared to the previous period [2]. - On February 2, 2025, Haohai Biological had a financing balance of 113 million yuan, accounting for 1.28% of its market capitalization, which is above the 50th percentile level over the past year [1]. - The company has cumulatively distributed dividends of 891 million yuan since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Business Overview - Haohai Biological, established on January 24, 2007, and listed on October 30, 2019, focuses on the research, production, and sales of medical devices and pharmaceuticals [1]. - The revenue composition of the company includes 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [1].

Core Viewpoint - Aibo Medical (688050.SH) plans to acquire at least 51% of Demai Medical, a leading sports medicine company, for a maximum valuation of 1 billion yuan, as a strategic move to diversify into the sports medicine sector amid challenges in its core ophthalmic business [3][12]. Group 1: Company Performance and Challenges - Aibo Medical has faced growth challenges, with its core artificial lens business, which has contributed nearly half of its revenue, experiencing pressure on profit margins due to price reductions following the inclusion in the national high-value medical consumables procurement [3][4]. - The sales volume of Aibo Medical's products increased by 44.93% in 2024, but revenue growth was only 17.66%, indicating a decline in average selling price from 437.56 yuan in 2022 to 338.06 yuan in 2024, with gross margin dropping from 84.75% in 2022 to 65.25% in the first half of 2025 [4][5]. - The company's stock price has significantly declined, dropping 49.94% from its peak of 117.65 yuan per share in October 2024 to a low of 58.89 yuan in December 2025, marking a new low since its listing [6][7]. Group 2: Market Dynamics and Competition - The OK lens business, seen as a potential growth driver, is facing intense competition from domestic players like Haohai Biological and Opcon Vision, leading to only single-digit growth in the near-sightedness prevention business in the first three quarters of 2025 [5]. - The strategic vision for the sports medicine market is promising, with an expected market size of 80-100 billion yuan by 2025, growing from 60-68 billion yuan in 2023, and a compound annual growth rate of 15%-20% [11]. Group 3: Acquisition Details and Financial Projections - Aibo Medical's acquisition target, Demai Medical, is a recognized domestic brand in sports medicine with a comprehensive product range and a strong patent portfolio, having transitioned from losses to profitability with adjusted net profits projected to grow significantly from 2023 to 2025 [12][13]. - The acquisition is structured with a performance commitment from Demai Medical's founder to achieve a cumulative net profit of at least 165 million yuan from 2026 to 2028, with specific annual targets [14]. - The valuation of 1 billion yuan corresponds to a price-to-earnings ratio of approximately 15.38 times based on the 2028 profit commitment, but this is significantly higher at 42.37 times based on the projected 2025 profit, indicating a high-risk investment [15]. Group 4: Integration Challenges and Risks - The integration of Aibo Medical and Demai Medical poses significant challenges due to differences in technology application, customer demographics, and clinical ecosystems, which may complicate the realization of synergistic benefits [16]. - Potential synergies exist in technology and sales channels, as Aibo Medical's expertise in biocompatible materials could enhance Demai Medical's product offerings, while their respective sales networks could support cross-promotion [17]. - Financial risks are present, with Demai Medical's liabilities increasing at a faster rate than revenue, and Aibo Medical's use of acquisition loans could heighten financial leverage, adding pressure if performance targets are not met [18].

回看蒋伟内幕交易过程，2024年6月26日，蒋伟与相关内幕信息知情人存在联络接触。2024年6月27日至 7月1日，蒋伟控制使用其本人及多个他人证券账户买入相关公司（即"*ST景峰"，下同）股票，内幕信 息公开后全部卖出，共计获利470.97万元。 经查，在2024年6月27日开始买入相关公司股票的同时，蒋伟还建议他人买入相关公司股票。上述违法 事实，有相关公司公告和文件、相关人员询问笔录、证券账户资料、交易流水、银行账户资料及资金流 水等证据证明，足以认定。 无独有偶，另一份行政处罚决定书中涉及的内幕信息同样指向*ST景峰的预重整。赵伟是内幕信息知情 人，其不晚于2024年5月17日知悉内幕信息。 【#最新内幕交易重罚落地#】1月9日，中国证监会同时发布两份行政处罚决定书，对两起内幕交易案件 作出严肃处理。涉案当事人蒋伟、赵伟分别利用上市公司预重整及引入重整投资人的内幕信息，在敏感 期内进行股票交易，合计获利逾647万元，最终被证监会没收全部违法所得，合计罚没金额约2640.38万 元。从行政处罚决定书来看，两起内幕交易均与一家上市公司预重整信息有关。 上海证券报记者根据上述内幕信息的时间点回查获悉，上述预 ...

1月9日，中国证监会同时发布两份行政处罚决定书，对两起内幕交易案件作出严肃处理。涉案当事人蒋 伟、赵伟分别利用上市公司预重整及引入重整投资人的内幕信息，在敏感期内进行股票交易，合计获利 逾647万元，最终被证监会没收全部违法所得，合计罚没金额约2640.38万元。 对此，证监会决定对蒋伟内幕交易行为，没收违法所得470.97万元，并处以1412.92万元元罚款；对蒋伟 建议他人买卖证券行为，处以50万元罚款。综合前述两项，对蒋伟累计罚没1933.89万元。 昊海生科2025年12月24日公告表示，该行政处罚决定书所涉主体为蒋伟先生个人，涉及的事项与公司无 关。蒋伟不参与公司日常经营管理，该事项不会对公司日常经营、业务及财务造成重大影响。截至公告 披露日，公司各项生产经营活动正常有序开展。 无独有偶，另一份行政处罚决定书中涉及的内幕信息同样指向*ST景峰的预重整。赵伟是内幕信息知情 人，其不晚于2024年5月17日知悉内幕信息。 从行政处罚决定书来看，两起内幕交易均与一家上市公司预重整信息有关。 2023年11月，相关公司公告，因债权人申请，人民法院同意对相关公司进行预重整。在预重整过程中， 相关公司引入重整投 ...